Pharming Group N.V.

PHAR Nasdaq SEC CIK 1828316
Follow Pharming Weekly email: filings, results

Financials

Reported figures only · latest: Q4 2025 USD · IFRS
EPS, diluted -

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, IFRS
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$100M$0$100M$200M$300M$400MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$376.1M$2.9M
FY24$297.2M−$11.8M
FY23$245.3M−$10.5M
FY22$205.6M$13.7M
FY21$198.9M$16M
FY20$212.2M$37.7M
FY19$189.4M$40.6M
FY18--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−25%0%25%50%75%100%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2587.9%6.9%0.8%
FY2488.1%−2.9%−4%
FY2389.7%−2.2%−4.3%
FY2291.5%8.9%6.7%
FY2189.4%6.8%8%
FY2088.9%35.9%17.8%
FY1987.4%36%21.4%
FY18---
Free cash flowOperating cash flow minus capital expenditure
−$25M$0$25M$50M$75M$100MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25$54M
FY24−$2.6M
FY23−$18.7M
FY22$21.1M
FY21$27.1M
FY20$79M
FY19$71.5M
FY18-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Pharming
  • Healthcare median
−100%−50%0%50%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearPharmingHealthcare median
FY250.8%−30.6%
FY24−4%−47%
FY23−4.3%−58%
FY226.7%−80.4%
FY218%−71.9%
FY2017.8%−62.2%
FY1921.4%−46.3%
FY18-−49.6%